News - Merck & Co, Global


Current filters:

Merck & CoGlobal

Popular Filters

Modest growth forecast for global migraine market to 2023

Modest growth forecast for global migraine market to 2023


The global migraine treatment market value is expected to undergo a modest increase over the coming years,…

CoLucid PharmaceuticalsGloballamiditanMarkets & MarketingMerck & CoMK-1602NeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

Global asthma market to reach 159 million lifetime cases by 2022


Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion.…

GlaxoSmithKlineGlobalMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySeretideSingulair

Merck & Co in-licenses Chimerix antiviral; Fiocruz to make ARVs in Africa


USA-based Chimerix, a venture-funded biotech focused on developing novel oral antivirals, has announced…

Anti-viralsChimerixCMX001CMX157FiocruzGlobalLicensingMarkets & MarketingMerck & CoPharmaceuticalRest of the World

Cancer vaccines market set to see change, will grow to over $9 billion by 2018


The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

Back to top